These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34202960)

  • 21. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thromboelastography with platelet mapping.
    Corliss BM; Polifka AJ; Harris NS; Hoh BL; Fox WC
    J Neurosurg; 2018 Nov; 129(5):1160-1165. PubMed ID: 29271717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Vavuranakis M; Maniatis K; Kokkou E; Papageorgiou N; Papaioannou S; Tourikis P; Papavassiliou AG; Stefanadis C; Tousoulis D
    Int J Cardiol; 2014 Nov; 177(1):192-6. PubMed ID: 25499376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
    Jimenez Diaz VA; Tello-Montoliu A; Moreno R; Cruz Gonzalez I; Baz Alonso JA; Romaguera R; Molina Navarro E; Juan Salvadores P; Paredes Galan E; De Miguel Castro A; Bastos Fernandez G; Ortiz Saez A; Fernandez Barbeira S; Raposeiras Roubin S; Ocampo Miguez J; Serra Peñaranda A; Valdes Chavarri M; Cequier Fillat A; Calvo Iglesias F; Iñiguez Romo A
    JACC Cardiovasc Interv; 2019 Jan; 12(1):22-32. PubMed ID: 30621974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
    Park TK; Song YB; Ahn J; Carriere KC; Hahn JY; Yang JH; Choi SH; Choi JH; Lee SH; Gwon HC
    Circ Cardiovasc Interv; 2016 Jan; 9(1):e002816. PubMed ID: 26755571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment.
    Kang HG; Lee SJ; Heo SH; Chang DI; Kim BJ
    Front Neurol; 2021; 12():652416. PubMed ID: 34447343
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
    Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
    Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
    van Diepen S; Fuster V; Verma S; Hamza TH; Siami FS; Goodman SG; Farkouh ME
    J Am Coll Cardiol; 2017 Jan; 69(2):119-127. PubMed ID: 28081820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
    Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C
    Circ J; 2014; 78(3):679-84. PubMed ID: 24389597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
    Chen YC; Lin FY; Lin YW; Cheng SM; Lin RH; Chuang CL; Sheu JS; Chen SM; Chang CC; Tsai CS
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):75-86. PubMed ID: 30467686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
    Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
    Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor.
    Kim J; Jang WJ; Lee WS; Choi KH; Lee JM; Park TK; Yang JH; Choi JH; Song YB; Choi SH; Gwon HC; Lee SH; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Hahn JY
    Heart; 2021 Jun; 107(13):1077-1083. PubMed ID: 33758008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.